CORE Chiropractic Voted Best Chiropractor for the 4th Consecutive Year
United States, August 2, 2025 -- CORE Chiropractic, a top-rated Houston chiropractic office, is delighted to announce it has, for the fourth time in a row, been awarded the prestigious Best Chiropracto r award by the Houston Chronicle. The award recognizes CORE Chiropractic's outstanding contributions to chiropractic care and its team's commitment to providing exceptional patient care. It is one of several accolades the clinic has accumulated this year.
Besides celebrating receiving the Best Chiropractor award, CORE Chiropractic is also celebrating another win: the Best Alternative Pain Management award, also given by the Houston Chronicle. The Houston chiropractor has won in this new category for two consecutive years, marking six straight appearances in the Houston Chronicle's Best of the Best Award list. However, CORE Chiropractic has not only been recognized as the best chiropractic office by Houston Chronicle, the clinic has also earned awards from ThreeBest Rated, Living Magazine's Best of, and H Town Best.
The accolades celebrate CORE Chiropractic's dedication to delivering client-focused, results-driven chiropractic care, from X-ray guided chiropractic methods to modern therapies, ensuring every client receives personalized, high-quality care. The clinic's consistency in integrating its unique CORE system approach to chiropractic care and fostering a patient-friendly environment for better patient outcomes has set it apart as one of the best Houston chiropractors.
'We are deeply honored to receive this prestigious award,' said Dr. Philip Cordova. 'This recognition reflects our collective passion and the dedication to outstanding customer service our team possesses. Our mission is to provide consistent, fast, and lasting relief and this award streak inspires to continue striving for excellence in everything we do.'
CORE Chiropractic's awards acknowledge its advanced chiropractic services and therapies, including spinal decompression therapy, Pulsed Electro Magnetic Field Therapy (PEMF), and High Energy Inductive Therapy (HEIT). By specializing in chiropractic care that addresses neck and back pain, sciatica, muscle strains, disc injuries, and other injuries, the clinic continues to establish itself as the leader in precision methods that ensure patient comfort. CORE Chiropractic is also widely recognized for its comprehensive approach, which involves educating patients on chiropractic care so that they can make informed decisions.
The clinic's services and commitment to customer service have significantly impacted chiropractic care in Houston. With these awards, CORE Chiropractic reaffirms its focus on addressing the root cause of pain without drugs or surgery, only chiropractic care.
In celebration of these prestigious achievements, CORE Chiropractic has announced that it will open its third location in Memorial City in January 2026. Dr. Natalie Cordova shared that with the new location, CORE Chiropractic looks forward to continuing its award streak by delivering unmatched services using the latest technology and chiropractic practices.
'We are not slowing down. Our awards and expansion are a testament to our leadership in chiropractic care in Houston. This new location will ensure we expand access to our services and remain at the forefront of chiropractic care, providing patients across Houston with the highest level of service.'
For more information, visit CORE Chiropractic.
Contact Info:
Name: Philip Cordova DC
Email: Send Email
Organization: CORE Chiropractic
Phone: 7136223300
Website: https://www.corechiropractic.net
Release ID: 89165916
If you come across any problems, discrepancies, or concerns related to the content contained within this press release that necessitate action or if a press release requires takedown, we strongly encourage you to reach out without delay by contacting [email protected] (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our committed team will be readily accessible round-the-clock to address your concerns within 8 hours and take appropriate actions to rectify identified issues or support with press release removals. Ensuring accurate and reliable information remains our unwavering commitment.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
25 minutes ago
- Yahoo
Castle Biosciences Reports Second Quarter 2025 Results
Delivered Q2 2025 revenue of $86 million Q2 2025 total test reports for our core revenue drivers (DecisionDx®-Melanoma, TissueCypher®) increased 33% over Q2 2024 Raising full-year 2025 revenue guidance range to $310-320 million from $287-297 million Conference call and webcast today at 4:30 p.m. ET FRIENDSWOOD, Texas, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the second quarter and six months ended June 30, 2025.'Following a strong first quarter, our team closed out a very successful second quarter that we believe continued to reflect the clinical value our tests provide to clinicians and their patients,' said Derek Maetzold, president and chief executive officer of Castle Biosciences. 'We saw very solid total year-over-year test volume growth in our core revenue drivers, with both DecisionDx-Melanoma and TissueCypher exceeding our volume expectations for the quarter, driving our top-line performance. 'In alignment with our capital allocation priorities and M&A strategy, we closed the Previse tuck-in acquisition and announced an exciting collaboration and license agreement with SciBase, both of which we believe will support our mid- to long-term value creation goals. At the same time, we remain deeply focused on execution across our current test portfolio, which we believe positions us well for continued near-term success. Our ability to invest in the future while advancing our core franchises reflects the strength of our growth initiatives and commitment to delivering sustainable value to our stakeholders.'Second Quarter Ended June 30, 2025, Financial and Operational Highlights Revenues were $86.2 million, compared to $87.0 million in the second quarter of 2024. Affecting second quarter 2025 revenue was the Novitas local coverage determination (LCD), Genetic Testing in Oncology: Specific Tests, that included DecisionDx®-SCC as noncovered, which became effective April 24, 2025, as well as discontinuation of IDgenetix® in May 2025. Adjusted Revenues, which exclude the effects of revenue adjustments related to tests delivered in prior periods, were $86.2 million, compared to $86.6 million for the same period in 2024. Delivered 26,574 total test reports in the second quarter of 2025, an increase of 6% compared to 25,102 in the same period of 2024. Affecting second quarter 2025 test report volume was the Novitas LCD, Genetic Testing in Oncology: Specific Tests, that included DecisionDx-SCC as noncovered, which became effective April 24, 2025, as well as discontinuation of IDgenetix in May 2025: DecisionDx-Melanoma test reports delivered in the quarter were 9,981, compared to 9,585 in the second quarter of 2024. TissueCypher Barrett's Esophagus test reports delivered in the quarter were 9,170, compared to 4,782 in the second quarter of 2024. DecisionDx-SCC test reports delivered in the quarter were 4,762, compared to 4,277 in the second quarter of 2024. Affecting second quarter test report volume was the Novitas LCD, Genetic Testing in Oncology: Specific Tests, that included DecisionDx-SCC as noncovered, which became effective April 24, 2025. MyPath® Melanoma test reports delivered in the quarter were 1,166, compared to 1,099 in the second quarter of 2024. IDgenetix test reports delivered in the quarter were 1,027, compared to 4,903 in the second quarter of 2024. The Company discontinued its IDgenetix test offering effective May 2025. DecisionDx®-UM test reports delivered in the quarter were 468, compared to 456 in the second quarter of 2024. Gross margin was 77%, and Adjusted Gross Margin was 80%, compared to 81% and 83%, respectively, for the same periods in 2024. Net cash provided by operations was $20.8 million, compared to net cash provided by operations of $24.0 million for the same period in 2024. Net income, which includes non-cash stock-based compensation expense of $11.2 million, was $4.5 million, compared to net income of $8.9 million for the same period in 2024. Net income per share and Adjusted Net Income per Share, Basic and Diluted, was $0.16 and $0.15, respectively, compared to $0.32 and $0.31, respectively, for the same period in 2024. Adjusted EBITDA was $10.4 million, compared to $21.5 million for the same period in 2024. Six Months Ended June 30, 2025, Financial and Operational Highlights Revenues were $174.2 million, a 9% increase compared to $160.0 million during the same period in 2024. Affecting six months ended June 30, 2025 revenue was the Novitas LCD, Genetic Testing in Oncology: Specific Tests, that included DecisionDx-SCC as noncovered, which became effective April 24, 2025, as well as discontinuation of IDgenetix in May 2025. Adjusted Revenues, which exclude the effects of revenue adjustments related to tests delivered in prior periods, were $176.2 million, an 11% increase compared to $159.0 million for the same period in 2024. Delivered 50,976 total test reports in the six months ended June 30, 2025, an increase of 11% compared to 45,990 in the same period of 2024. Affecting six months ended June 30, 2025 test report volume was the Novitas LCD, Genetic Testing in Oncology: Specific Tests, that included DecisionDx-SCC as noncovered, which became effective April 24, 2025, as well as discontinuation of IDgenetix in May 2025: DecisionDx-Melanoma test reports delivered in the six months ended June 30, 2025, were 18,602, compared to 17,969 for the same period in 2024. TissueCypher Barrett's Esophagus test reports delivered in the six months ended June 30, 2025, were 16,602, compared to 8,211 for the same period in 2024. DecisionDx-SCC test reports delivered in the six months ended June 30, 2025, were 9,137, compared to 7,854 for the same period in 2024. Affecting six months ended June 30, 2025 volume was the Novitas LCD, Genetic Testing in Oncology: Specific Tests, that included DecisionDx-SCC as noncovered, which became effective April 24, 2025. MyPath Melanoma test reports delivered in the six months ended June 30, 2025, were 2,092, compared to 2,097 for the same period in 2024. IDgenetix test reports delivered in the six months ended June 30, 2025, were 3,605, compared to 8,981 for the same period in 2024. The Company discontinued its IDgenetix test offering effective May 2025. DecisionDx-UM test reports delivered in the six months ended June 30, 2025, were 938, compared to 878 for the same period in 2024. Gross margin for the six months ended June 30, 2025, was 63%, and Adjusted Gross Margin was 81%. Net cash provided by operations was $14.8 million, compared to $17.2 million net cash provided by operations for the same period in 2024. Net loss, which includes non-cash stock-based compensation expense of $22.4 million, was $21.3 million, compared to net income of $6.4 million for the same period in 2024. Net loss per share, Basic and Diluted, was $0.74 and Adjusted Net Loss per Share, Basic and Diluted, was $0.04, compared to Net income per share and Adjusted Net Income per Share, Basic and Diluted, of $0.23 and $0.22, respectively, for the same period in 2024. Adjusted EBITDA was $23.4 million, compared to $32.1 million for the same period in 2024. Cash, Cash Equivalents and Marketable Investment Securities As of June 30, 2025, the Company's cash, cash equivalents and marketable investment securities totaled $275.9 million. 2025 Outlook Castle Biosciences is raising its guidance for anticipated total revenue in 2025. The Company now anticipates generating between $310-320 million in total revenue in 2025, compared to the previously provided guidance of between $287-297 million. Second Quarter and Recent Accomplishments and HighlightsDecisionDx-Melanoma: DecisionDx-Melanoma test has been granted Breakthrough Device designation from the U.S. Food and Drug Administration (FDA). The FDA grants Breakthrough Device designation to select qualifying devices that may offer improved treatment or diagnosis of life-threatening or irreversibly debilitating diseases when compared to currently available alternatives. The Breakthrough Devices Program is intended to provide patients and healthcare providers with timely access to medical devices by speeding up development, assessment and review. See the Company's news release from July 23, 2025, for more information. DecisionDx-Melanoma: Prior studies have shown that clinicians use DecisionDx-Melanoma to inform both avoiding sentinel lymph node biopsy procedures in low-risk patients and initiation of surveillance imaging and referrals to medical oncology in high-risk patients, which enables early detection of recurrences and initiation of therapy. Early detection has been shown to improve outcomes to a greater extent when therapy is initiated with smaller metastatic burden, which can improve net health outcomes. The Company presented novel research as part of Castle's ongoing collaboration with the NCI's SEER Program Registries at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The study presented an updated matching of patients who received DecisionDx-Melanoma as part of their clinical care to those who did not. In this large, real-world cohort of 13,560 patients with CM – the largest real-world study of gene expression profile testing to date – the DecisionDx-Melanoma was associated with a 32% reduction in mortality risk compared to untested patients, providing further evidence of the test's association with improved patient survival. Additionally, test performance on independent risk stratification was re-confirmed. See the Company's news release from May 29, 2025, for more information. DecisionDx-SCC: The Company submitted a DecisionDx-SCC reconsideration request for the Novitas LCD and received notification confirming acceptance of the reconsideration submission. DecisionDx-SCC: Two new studies were published in SKIN The Journal of Cutaneous Medicine supporting the clinical utility of DecisionDx-SCC in patients with high-risk cutaneous squamous cell carcinoma (SCC). The first study represents a new validation milestone, establishing DecisionDx-SCC as a significant predictor of local recurrence (LR) in patients classified as high-risk by National Comprehensive Cancer Network (NCCN) guidelines, thereby adding a third utility to the test's existing capabilities. The test has now been validated to predict individual risk of metastasis, benefit from adjuvant radiation therapy (ART) and risk of LR, providing comprehensive results to support tailored post-surgical management and treatment pathway recommendations for patients with SCC. The second study shares results from a clinician survey, affirming the impact of the test's results in guiding these recommendations, specifically the use of ART and surveillance imaging, by providing actionable decision points based on individual patient Company closed its acquisition of Capsulomics, Inc., d/b/a Previse. This acquisition has the potential to increase Castle's GI offerings. There is the potential to create a multiomics approach for improved patient care in Barrett's esophagus, as well as a nonendoscopic sample collection device for pipeline opportunities to potentially expand screening and diagnostic support for patients with Barrett's esophagus and other GI diseases. See the Company's news release from May 5, 2025, for more Company announced new data from the first independent validation of the recently published Collaborative Ocular Oncology Group Study No. 2 (COOG2.) by Harbour et al. The data, from a real-world cohort of 1,297 patients with uveal melanoma (UM), was presented at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting in Salt Lake City. The findings provided further support for adding Preferentially Expressed Antigen in Melanoma (PRAME) gene expression information to the DecisionDx-UM test result to further refine metastatic risk prediction for patients with UM, which is a rare but aggressive eye cancer. See the Company's news release from May 9, 2025, for more Company announced that it entered into a collaboration and license agreement with SciBase Holding AB ('SciBase') utilizing SciBase's Electrical Impedance Spectroscopy technology, which includes both desktop and point-of-care instruments. The initial goal of the collaboration is to advance the development of a diagnostic test that predicts flares in patients diagnosed with atopic dermatitis (AD), a U.S., market with an estimated up to 24 million patients.1,2 See the Company's news release from June 16, 2025, for more Company announced that its founder, president and chief executive officer Derek Maetzold was awarded a distinguished Lifetime Achievement Award in the Management: Business Products Industries category in the 23rd Annual American Business Awards. The American Business Awards recognizes outstanding business performances in the United States, with more than 3,600 nominations from organizations of all sizes submitted this year for consideration in a wide range of categories. See the Company's news release from June 4, 2025, for more information. The Company announced that it earned multiple awards through the 2025 Top Workplaces program: a third consecutive national Healthcare Industry Top Workplaces award, with Castle ranking third among other recognized companies in its size bracket; a fourth consecutive regional Arizona Top Workplaces award from AZ Central; and consecutive national Top Workplaces Culture Excellence awards for Innovation, Work-Life Flexibility, Compensation & Benefits, Leadership and Purpose & Values. Top Workplaces award designations are garnered solely through anonymous employee feedback gathered through a third-party survey administered by Energage. The confidential survey measures the workplace experience and various culture themes that are indicative of successful organizations. See the Company's news release from July 17, 2025, for more information. The Company announced that Maetzold was also named a 2025 Most Admired CEO by the Houston Business Journal. This prestigious honor celebrates leaders who have demonstrated outstanding financial stewardship, fostered inclusive and thriving workplace cultures, and made meaningful contributions to the greater Houston community. See the Company's news release from July 25, 2025, for more information. Conference Call and Webcast Details Castle Biosciences will hold a conference call on Monday, August 4, 2025, at 4:30 p.m. Eastern time to discuss its second quarter 2025 results and provide a corporate update. A live webcast of the conference call can be accessed here: or via the webcast link on the Investor Relations page of the Company's website, Please access the webcast at least 10 minutes before the conference call start time. An archive of the webcast will be available on the Company's website until August 25, 2025. To access the live conference call via phone, please dial 833 470 1428 from the United States, or +1 404 975 4839 internationally, at least 10 minutes prior to the start of the call, using the conference ID 638217. There will be a brief Question & Answer session following management commentary. Use of Non-GAAP Financial Measures (UNAUDITED) In this release, we use the metrics of Adjusted Revenues, Adjusted Gross Margin, Adjusted EBITDA and Adjusted Net Income (Loss) per Share, Basic and Diluted, which are non-GAAP financial measures and are not calculated in accordance with generally accepted accounting principles in the United States (GAAP). Adjusted Revenues and Adjusted Gross Margin reflect adjustments to GAAP net revenues to exclude net positive and/or net negative revenue adjustments recorded in the current period associated with changes in estimated variable consideration related to test reports delivered in previous periods. Adjusted Gross Margin further excludes acquisition-related intangible asset amortization. Adjusted EBITDA excludes from net income (loss): interest income, interest expense, income tax benefit, depreciation and amortization expense, stock-based compensation expense and changes in fair value of trading securities. Adjusted Net Income (Loss) per Share, Basic and Diluted, excludes a one-time adjustment of an acceleration of amortization expense for our IDgenetix test from net income (loss). We use Adjusted Revenues, Adjusted Gross Margin, Adjusted EBITDA and Adjusted Net Income (Loss) per Share, Basic and Diluted, internally because we believe these metrics provide useful supplemental information in assessing our revenue and operating performance reported in accordance with GAAP, respectively. We believe that Adjusted Revenues, when used in conjunction with our test report volume information, facilitates investors' analysis of our current-period revenue performance and average selling price performance by excluding the effects of revenue adjustments related to test reports delivered in prior periods, since these adjustments may not be indicative of the current or future performance of our business. We believe that providing Adjusted Revenues may also help facilitate comparisons to our historical periods. Adjusted Gross Margin is calculated using Adjusted Revenues and therefore excludes the impact of revenue adjustments related to test reports delivered in prior periods, which we believe is useful to investors as described above. We further exclude acquisition-related intangible asset amortization in the calculation of Adjusted Gross Margin. We believe that excluding acquisition-related intangible asset amortization may facilitate gross margin comparisons to historical periods and may be useful in assessing current-period performance without regard to the historical accounting valuations of intangible assets, which are applicable only to tests we acquired rather than internally developed. Adjusted Net Income (Loss) per Share, Basic and Diluted, is calculated by excluding a one-time adjustment of an acceleration of amortization expense for our IDgenetix test from net loss. We believe that providing Adjusted Net Income (Loss) per Share, Basic and Diluted, may also help facilitate comparisons to our historical periods. We believe Adjusted EBITDA may enhance an evaluation of our operating performance because it excludes the impact of prior decisions made about capital investment, financing, investing and certain expenses we believe are not indicative of our ongoing performance. However, these non-GAAP financial measures may be different from non-GAAP financial measures used by other companies, even when the same or similarly titled terms are used to identify such measures, limiting their usefulness for comparative purposes. These non-GAAP financial measures are not meant to be considered in isolation or used as substitutes for net revenues, gross margin net income (loss) or net income (loss) per share reported in accordance with GAAP; should be considered in conjunction with our financial information presented in accordance with GAAP; have no standardized meaning prescribed by GAAP; are unaudited; and are not prepared under any comprehensive set of accounting rules or principles. In addition, from time to time in the future, there may be other items that we may exclude for purposes of these non-GAAP financial measures, and we may in the future cease to exclude items that we have historically excluded for purposes of these non-GAAP financial measures. Likewise, we may determine to modify the nature of adjustments to arrive at these non-GAAP financial measures. Because of the non-standardized definitions of non-GAAP financial measures, the non-GAAP financial measure as used by us in this press release and the accompanying reconciliation tables have limits in their usefulness to investors and may be calculated differently from, and therefore may not be directly comparable to, similarly titled measures used by other companies. Accordingly, investors should not place undue reliance on non-GAAP financial measures. Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures are presented in the tables at the end of this release. About Castle Biosciences Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors. Castle's current portfolio consists of tests for skin cancers, Barrett's esophagus and uveal melanoma. Additionally, the Company has active research and development programs for tests in these and other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis seeking biologic treatment. To learn more, please visit and connect with us on LinkedIn, Facebook, X and Instagram. DecisionDx-Melanoma, DecisionDx-CMSeq, i31-SLNB, i31-ROR, DecisionDx-SCC, MyPath Melanoma, TissueCypher, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc. Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the 'safe harbor' created by those sections. These forward-looking statements include, but are not limited to, statements concerning our expectations regarding: Castle's 2025 total revenue guidance of $310-320 million; continued top-line performance and growth of test volumes; the potential mid- to long-term value possibly generated from the Previse and SciBase transactions; the ability of DecisionDx-Melanoma and DecisionDx-SCC to bring substantial added value to clinicians and their patients; the ability of DecisionDx-Melanoma to (i) reduce mortality risk compared to untested patients and (ii) improve patient survival; the ability of DecisionDx-SCC to (i) predict individual risk of metastasis, benefit from /ART and risk of LR and (ii) provide comprehensive results to support tailored post-surgical management and treatment pathway recommendations; the success of Castle's DecisionDx-SCC reconsideration request for the Novitas LCD determination; and Castle's ability to achieve near- and long-term success and the continued growth of our portfolio. The words 'anticipate,' 'can,' 'could,' 'expect,' 'goal,' 'may,' 'plan' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We may not actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that we make. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from those in the forward-looking statements, including, without limitation: our assumptions or expectations regarding reimbursement for our products and subsequent coverage decisions, our estimated total addressable markets for our products and product candidates and the related expenses, capital requirements and potential needs for additional financing, the anticipated cost, timing and success of our product candidates, and our plans to research, develop and commercialize new tests and our ability to successfully integrate new businesses, assets, products or technologies acquired through acquisitions, the effects of macroeconomic events and conditions, including inflation and monetary supply shifts, labor shortages, liquidity concerns at, and failures of, banks and other financial institutions or other disruptions in the banking system or financing markets and recession risks, supply chain disruptions, tariffs, outbreaks of contagious diseases and geopolitical events (such as the ongoing conflicts in the Middle East and Ukraine-Russia conflict), among others, on our business and our efforts to address its impact on our business; the possibility that subsequent study or trial results and findings may contradict earlier study or trial results and findings or may not support the results discussed in this press release, including with respect to the tests discussed in this press release; our planned installation of additional equipment and supporting technology infrastructures and implementation of certain process efficiencies may not enable us to increase the future scalability of our TissueCypher Test; the possibility that actual application of our tests may not provide the aforementioned benefits to patients; the possibility that our newer gastroenterology franchise may not contribute to the achievement of our long-term financial targets as anticipated; and the risks set forth under the heading 'Risk Factors' in our Annual Report on Form 10-K for the year ended December 31, 2024 and our Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, each filed or to be filed with the SEC, and in our other filings with the SEC. The forward-looking statements are applicable only as of the date on which they are made, and we do not assume any obligation to update any forward-looking statements, except as may be required by law. Investor Relations Contact: Camilla Zuckeroczuckero@ Media Contact: Allison Marshall amarshall@ CASTLE BIOSCIENCES, CONSOLIDATED STATEMENTS OF OPERATIONS(UNAUDITED)(in thousands, except per share data) Three Months EndedJune 30, Six Months EndedJune 30, 2025 2024 2025 2024 NET REVENUES $ 86,188 $ 87,002 $ 174,176 $ 159,976 OPERATING EXPENSES Cost of sales (exclusive of amortization of acquired intangible assets) 17,626 14,519 34,009 28,413 Research and development 12,787 14,136 25,375 27,945 Selling, general and administrative 58,065 51,088 116,685 99,583 Amortization of acquired intangible assets 1,961 2,247 30,286 4,494 Total operating expenses, net 90,439 81,990 206,355 160,435 Operating (loss) income (4,251 ) 5,012 (32,179 ) (459 ) Interest income 2,944 3,144 6,043 6,140 Changes in fair value of trading securities 1,185 — (240 ) — Interest expense (21 ) (270 ) (38 ) (284 ) (Loss) income before income taxes (143 ) 7,886 (26,414 ) 5,397 Income tax benefit (4,666 ) (1,034 ) (5,089 ) (989 ) Net income (loss) $ 4,523 $ 8,920 $ (21,325 ) $ 6,386 Earnings (loss) per share: Basic $ 0.16 $ 0.32 $ (0.74 ) $ 0.23 Diluted $ 0.15 $ 0.31 $ (0.74 ) $ 0.22 Weighted-average shares outstanding: Basic 28,914 27,646 28,763 27,566 Diluted 29,545 28,738 28,763 28,542 Stock-based compensation expense is included in the unaudited condensed consolidated statements of operations as follows (in thousands): Three Months EndedJune 30, Six Months EndedJune 30, 2025 2024 2025 2024 Cost of sales (exclusive of amortization of acquired intangible assets) $ 1,422 $ 1,401 $ 2,878 $ 2,715 Research and development 1,962 2,637 3,857 5,266 Selling, general and administrative 7,824 9,141 15,652 17,873 Total stock-based compensation expense $ 11,208 $ 13,179 $ 22,387 $ 25,854 CASTLE BIOSCIENCES, CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME(UNAUDITED)(in thousands) Three Months EndedJune 30, Six Months EndedJune 30, 2025 2024 2025 2024 Net income (loss) $ 4,523 $ 8,920 $ (21,325 ) $ 6,386 Other comprehensive loss: Net unrealized loss on marketable investment securities (92 ) (61 ) (191 ) (308 ) Comprehensive income (loss) $ 4,431 $ 8,859 $ (21,516 ) $ 6,078 CASTLE BIOSCIENCES, CONSOLIDATED BALANCE SHEETS(in thousands) June 30, 2025 December 31, 2024 ASSETS (unaudited) Current Assets Cash and cash equivalents $ 82,233 $ 119,709 Marketable investment securities 193,697 173,421 Accounts receivable, net 52,311 51,218 Inventory 8,366 8,135 Prepaid expenses and other current assets 12,061 7,671 Total current assets 348,668 360,154 Long-term accounts receivable, net 1,132 918 Property and equipment, net 74,060 51,122 Operating lease assets 15,503 11,584 Goodwill and other intangible assets, net 104,125 106,229 Other assets – long-term 1,241 1,228 Total assets $ 544,729 $ 531,235 LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities Accounts payable $ 13,181 $ 6,901 Accrued compensation 24,973 32,555 Contingent consideration 1,000 — Operating lease liabilities 1,571 1,665 Current portion of long-term debt 1,944 278 Other accrued and current liabilities 8,221 7,993 Total current liabilities 50,890 49,392 Long-term debt 8,096 9,745 Noncurrent portion of contingent consideration 1,500 — Noncurrent operating lease liabilities 25,377 14,345 Noncurrent finance lease liabilities 364 311 Deferred tax liability 3,126 1,607 Total liabilities 89,353 75,400 Stockholders' Equity Preferred stock — — Common stock 29 28 Additional paid-in capital 676,759 655,703 Accumulated deficit (221,451 ) (200,126 ) Accumulated other comprehensive income 39 230 Total stockholders' equity 455,376 455,835 Total liabilities and stockholders' equity $ 544,729 $ 531,235 CASTLE BIOSCIENCES, CONSOLIDATED STATEMENTS OF CASH FLOWS(UNAUDITED)(in thousands) Six Months EndedJune 30, 2025 2024 OPERATING ACTIVITIES Net (loss) income $ (21,325 ) $ 6,386 Adjustments to reconcile net (loss) income to net cash used in operating activities: Depreciation and amortization 33,178 6,688 Stock-based compensation expense 22,387 25,854 Change in fair value of trading securities 240 — Deferred income taxes (5,437 ) (1,542 ) Accretion of discounts on marketable investment securities (2,606 ) (3,422 ) Other 219 83 Change in operating assets and liabilities: Accounts receivable (1,307 ) (7,620 ) Prepaid expenses and other current assets (4,696 ) (294 ) Inventory (231 ) (71 ) Operating lease assets 664 678 Other assets (13 ) 143 Accounts payable 1,689 (1,650 ) Operating lease liabilities (869 ) (432 ) Accrued compensation (7,582 ) (7,706 ) Other accrued and current liabilities 474 68 Net cash provided by operating activities 14,785 17,163 INVESTING ACTIVITIES Purchases of marketable investment securities (92,832 ) (113,194 ) Proceeds from maturities of marketable investment securities 80,300 86,450 Purchases of debt securities classified as held-to-maturity (5,569 ) — Asset acquisition, net of cash and cash equivalents acquired (18,726 ) — Purchases of property and equipment (14,003 ) (14,381 ) Proceeds from sale of property and equipment 21 7 Net cash used in investing activities (50,809 ) (41,118 ) FINANCING ACTIVITIES Proceeds from exercise of common stock options 37 73 Payment of employees' taxes on vested restricted stock units (3,104 ) (1,089 ) Proceeds from contributions to the employee stock purchase plan 1,482 1,749 Repayment of principal portion of finance lease liabilities (57 ) (47 ) Proceeds from lease incentives received 190 — Proceeds from issuance of term debt — 10,000 Net cash (used in) provided by financing activities (1,452 ) 10,686 NET CHANGE IN CASH AND CASH EQUIVALENTS (37,476 ) (13,269 ) Beginning of period 119,709 98,841 End of period $ 82,233 $ 85,572 CASTLE BIOSCIENCES, INC. Reconciliation of Non-GAAP Financial Measures (UNAUDITED) The table below presents the reconciliation of Adjusted Revenues, Adjusted Gross Margin and Adjusted Net Income (Loss) Per Share, Basic and Diluted, which are non-GAAP financial measures. See "Use of Non-GAAP Financial Measures (UNAUDITED)" above for further information regarding the Company's use of non-GAAP financial measures. Three Months EndedJune 30, Six Months EndedJune 30, 2025 2024 2025 2024 (in thousands, except per share data) Adjusted Revenues Net revenues (GAAP) $ 86,188 $ 87,002 $ 174,176 $ 159,976 Revenue associated with test reports delivered in prior periods (6 ) (363 ) 1,996 (959 ) Adjusted Revenues (Non-GAAP) $ 86,182 $ 86,639 $ 176,172 $ 159,017 Adjusted Gross Margin Gross margin (GAAP)1 $ 66,601 $ 70,236 $ 109,881 $ 127,069 Amortization of acquired intangible assets 1,961 2,247 30,286 4,494 Revenue associated with test reports delivered in prior periods (6 ) (363 ) 1,996 (959 ) Adjusted Gross Margin (Non-GAAP) $ 68,556 $ 72,120 $ 142,163 $ 130,604 Gross Margin percentage (GAAP)2 77.3 % 80.7 % 63.1 % 79.4 % Adjusted Gross Margin percentage (Non-GAAP)3 79.5 % 83.2 % 80.7 % 82.1 % Adjusted Net Income (Loss) per Share, Basic and Diluted Net income (loss) (GAAP) $ 4,523 $ 8,920 $ (21,325 ) $ 6,386 Amortization of acquired intangible assets4 — — 20,099 — Adjusted Net Income (Loss) (Non-GAAP) $ 4,523 $ 8,920 $ (1,226 ) $ 6,386 Weighted-average shares outstanding Basic 28,914 27,646 28,763 27,566 Diluted 29,545 28,738 28,763 28,542 Net income (loss) per share (GAAP)5 Basic $ 0.16 $ 0.32 $ (0.74 ) $ 0.23 Diluted $ 0.15 $ 0.31 $ (0.74 ) $ 0.22 Adjusted Net Income (Loss) per share (Non-GAAP)6 Basic $ 0.16 $ 0.32 $ (0.04 ) $ 0.23 Diluted $ 0.15 $ 0.31 $ (0.04 ) $ 0.22 Calculated as net revenues (GAAP) less the sum of cost of sales (exclusive of amortization of acquired intangible assets) and amortization of acquired intangible assets. Calculated as gross margin (GAAP) divided by net revenues (GAAP). Calculated as Adjusted Gross Margin (Non-GAAP) divided by Adjusted Revenues (Non-GAAP). Represents a one-time adjustment of an acceleration of amortization expense for our IDgenetix test during the three months ended March 31,2025. Calculated as net income (loss) (GAAP) divided by weighted-average shares outstanding, basic and diluted. Calculated as Adjusted Net Income (Loss) (Non-GAAP) divided by weighted-average shares outstanding, basic and diluted. The table below presents the reconciliation of Adjusted EBITDA, which is a non-GAAP financial measure. See "Use of Non-GAAP Financial Measures (UNAUDITED)" above for further information regarding the Company's use of non-GAAP financial measures. Three Months EndedJune 30, Six Months EndedJune 30, 2025 2024 2025 2024 (in thousands) Adjusted EBITDA Net income (loss) $ 4,523 $ 8,920 $ (21,325 ) $ 6,386 Interest income (2,944 ) (3,144 ) (6,043 ) (6,140 ) Interest expense 21 270 38 284 Income tax benefit (4,666 ) (1,034 ) (5,089 ) (989 ) Depreciation and amortization expense 3,414 3,348 33,178 6,688 Stock-based compensation expense 11,208 13,179 22,387 25,854 Change in fair value of trading securities (1,185 ) — 240 — Adjusted EBITDA (Non-GAAP) $ 10,371 $ 21,539 $ 23,386 $ 32,083 1
Yahoo
25 minutes ago
- Yahoo
Dunham House to Partner with CrossMed Healthcare Staffing
Dunham House will partner with CrossMed Healthcare Staffing OMAHA, Neb., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Dunham House, a first-of-its-kind, transformational initiative for combat-wounded veterans in need of long-term residential-centered care for their wounds, will partner with Omaha-based CrossMed Healthcare Staffing to fill medical staffing needs. Omaha-based CrossMed Healthcare Staffing specializes in connecting traveling healthcare professionals with exceptional travel assignments across the nation. CrossMed's team helps healthcare professionals explore travel opportunities in hospitals, clinics and other healthcare facilities – all while offering personalized support throughout the process. 'CrossMed is guided by core values of being humble, accountable and relentless. These are attributes we seek in partners prior to veterans moving into Dunham House in fall 2026,' Wounded Warriors Family Support CEO and President Kate McCauley said. Dunham House will be situated on a scenic 40-acre site in north Omaha to allow for multi-phase construction. The $13.9 million project will serve as a long-term residential community for 30 veterans who require supportive care, while seeking to maintain their independence. The single-story complex will span approximately 27,500 square feet. It will house assisted living-style one-bedroom apartments along with specialized units for residents with greater physical needs. In addition to personalized care, residents will benefit from community-focused spaces, such as a great room, dining area, fitness center and memorial plaza. Dunham House is an initiative and project development with Omaha-based nonprofit Wounded Warriors Family Support. It will be part of the Wounded Warriors Family Support programming and operational scope. Donors can help build Dunham House for $25 a month. A commitment to donate $25 monthly builds 1 square foot. About Dunham House will provide combat-wounded veterans with top-level care and a supportive community where they can live with dignity and independence. Dunham House includes housing and amenities to accommodate 30 veterans in Omaha, Nebraska. Dunham House is an initiative and project development with Omaha-based nonprofit Wounded Warriors Family Support. For more information about Dunham House, visit About Wounded Warriors Family Support is an independent nonprofit organization whose mission is to provide support to the families of those who have been wounded, injured or killed during combat operations. Combat veterans run this organization for combat veterans. Rated a four-star nonprofit by Charity Navigator, Wounded Warriors Family Support aids veterans and their families in healing the wounds that medicine cannot. For more information about Wounded Warriors Family Support, visit Media Contact:Kevin Schuster, Public Relations Counsel Cell: 402.917.6001 Email: kschuster@ A photo accompanying this announcement is available at in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
25 minutes ago
- Yahoo
Encompass Health reports results for second quarter 2025
Increases full-year guidance BIRMINGHAM, Ala., Aug. 4, 2025 /PRNewswire/ -- Encompass Health Corporation (NYSE: EHC), the largest owner and operator of inpatient rehabilitation hospitals in the United States, today reported its results of operations for the second quarter ended June 30, 2025. Summary resultsGrowthQ2 2025Q2 2024DollarsPercent(In Millions, Except Per Share Data) Net operating revenue $ 1,457.7$ 1,301.2$ 156.512.0 % Income from continuing operations attributable toEncompass Health per diluted share 1.401.130.2723.9 % Adjusted earnings per share 1.401.110.2926.1 % Cash flows provided by operating activities 270.2217.452.824.3 % Adjusted EBITDA 318.6271.846.817.2 % Adjusted free cash flow 185.9142.543.430.5 % (Actual Amounts)Discharges 65,23760,8337.2 % Same-store discharge growth 4.7 % Net patient revenue per discharge $ 21,670$ 20,8034.2 % See attached supplemental information for calculations of non-GAAP measures and reconciliations to their most comparable GAAP measure. Revenue growth of 12.0% resulted from increased discharges and pricing. Total discharges grew 7.2%, inclusive of same-store growth of 4.7%. Net patient revenue per discharge grew 4.2%. Cash flows provided by operating activities increased 24.3% to $270.2 million, primarily due to an increase in net income. Adjusted EBITDA increased 17.2% from increased revenue and expense leverage. "During the quarter, we further increased our capacity to serve patients in need of inpatient rehabilitation care, opening a new 60-bed hospital in Fort Myers, Florida, and adding 26 beds to an existing hospital," said President and Chief Executive Officer Mark Tarr. "Our clinical expertise and commitment to delivering high-quality, cost-effective care continues to benefit our patients, referral sources and payors." 2025 Guidance The Company increased its full-year guidance as follows:Full-Year 2025 GuidancePrevious GuidanceUpdated Guidance(In Millions, Except Per Share Data) Net operating revenue $5,850 to $5,925$5,880 to $5,980 Adjusted EBITDA $1,185 to $1,220$1,220 to $1,250 Adjusted earnings per share from continuing operationsattributable to Encompass Health $4.85 to $5.10$5.12 to $5.34 For considerations regarding the Company's 2025 guidance, see the supplemental information posted on the Company's website at See also the "Other information" section below for an explanation of why the Company does not provide guidance for comparable GAAP measures for Adjusted EBITDA and adjusted earnings per share. Earnings conference call and webcast The Company will host an investor conference call at 10:00 a.m. Eastern Time on Tuesday, August 5, 2025 to discuss its results for the second quarter of 2025. For reference during the call, the Company will post certain supplemental information at The conference call may be accessed by dialing 800 343-4849 and giving the conference ID EHCQ225. International callers should dial 203 518-9848 and give the same conference ID. Please call approximately ten minutes before the start of the call to ensure you are connected. The conference call will also be webcast live and will be available for on-line replay at by clicking on an available link. About Encompass Health Encompass Health (NYSE: EHC) is the largest owner and operator of inpatient rehabilitation hospitals in the United States. With a national footprint that includes 169 hospitals in 38 states and Puerto Rico, the Company provides high-quality, compassionate rehabilitative care for patients recovering from a major injury or illness, using advanced technology and innovative treatments to maximize recovery. Encompass Health is ranked as one of Fortune's World's Most Admired Companies™, and Forbes' Most Trusted Companies in America.1 For more information, visit or follow us on our newsroom, X, Instagram and Facebook. 1 Fortune © 2025 Fortune Media IP Limited. All rights reserved. Fortune® is a registered trademark and Fortune World's Most Admired Companies™ is a trademark of Fortune Media IP Limited and are used under license. Fortune and Fortune Media IP Limited are not affiliated with, and do not endorse products or services of, Encompass Health. Forbes © 2024 Forbes Media LLC. All rights reserved. Used under license. Other information The information in this press release is summarized and should be read in conjunction with the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 (the "June 2025 Form 10-Q"), when filed, as well as the Company's Current Report on Form 8-K filed on August 4, 2025 (the "Q2 Earnings Form 8-K"), to which this press release is attached as Exhibit 99.1. In addition, the Company will post supplemental information today on its website at for reference during its August 5, 2025 earnings call. The financial data contained in the press release and supplemental information include non-GAAP financial measures, including the Company's adjusted earnings per share, leverage ratio, Adjusted EBITDA, and adjusted free cash flow. Reconciliations to their most comparable GAAP measure, except with regard to non-GAAP guidance, are included below or in the Q2 Earnings Form 8-K. Readers are encouraged to review the "Note Regarding Presentation of Non-GAAP Financial Measures" included in the Q2 Earnings Form 8-K which provides further explanation and disclosure regarding the Company's use of these non-GAAP financial measures. Excluding net operating revenues, the Company does not provide guidance on a GAAP basis because it is unable to predict, with reasonable certainty, the future impact of items that are deemed to be outside the control of the Company or otherwise not indicative of its ongoing operating performance. Such items include government, class action, and related settlements; professional fees—accounting, tax, and legal; mark-to-market adjustments for stock appreciation rights; gains or losses related to hedging instruments; loss on early extinguishment of debt; adjustments to its income tax provision (such as valuation allowance adjustments and settlements of income tax claims); items related to corporate and facility restructurings; and certain other items the Company believes to be not indicative of its ongoing operations. These items cannot be reasonably predicted and will depend on several factors, including industry and market conditions, and could be material to the Company's results computed in accordance with GAAP. However, the following reasonably estimable GAAP measures for 2025 would be included in a reconciliation for Adjusted EBITDA if the other reconciling GAAP measures could be reasonably predicted: Interest expense and amortization of debt discounts and fees - approximately $125 million Amortization of debt-related items - approximately $10 million The Q2 Earnings Form 8-K and, when filed, the June 2025 Form 10-Q can be found on the Company's website at and the SEC's website at Encompass Health Corporation and SubsidiariesCondensed Consolidated Statements of Operations(Unaudited) Three Months Ended June 30,Six Months Ended June 30,2025202420252024(In Millions, Except Per Share Data) Net operating revenues $ 1,457.7$ 1,301.2$ 2,913.1$ 2,617.2 Operating expenses:Salaries and benefits 767.7700.51,530.01,412.1 Other operating expenses 213.8189.9431.3393.8 Occupancy costs 14.714.229.628.2 Supplies 63.157.6125.3116.1 General and administrative expenses 59.450.5111.7100.7 Depreciation and amortization 79.972.9159.1143.2 Total operating expenses 1,198.61,085.62,387.02,194.1 Interest expense and amortization of debt discounts and fees 30.434.362.269.5 Other income (6.7)(3.3)(9.2)(8.7) Equity in net income of nonconsolidated affiliates (1.4)(1.4)(2.3)(2.1) Income from continuing operations before income tax expense 236.8186.0475.4364.4 Provision for income tax expense 51.038.392.676.6 Income from continuing operations 185.8147.7382.8287.8 Loss from discontinued operations, net of tax (0.9)(1.2)(1.4)(2.5) Net income 184.9146.5381.4285.3 Less: Net income attributable to noncontrolling interests (42.8)(32.4)(87.8)(58.7) Net income attributable to Encompass Health $ 142.1$ 114.1$ 293.6$ 226.6 Weighted average common shares outstanding:Basic 100.699.9100.699.9 Diluted 102.3102.0102.2102.1 Earnings per common share:Basic earnings per share attributable to Encompass Health common shareholders:Continuing operations $ 1.42$ 1.14$ 2.92$ 2.28 Discontinued operations (0.01)(0.01)(0.01)(0.03) Net income $ 1.41$ 1.13$ 2.91$ 2.25 Diluted earnings per share attributable to Encompass Health common shareholders:Continuing operations $ 1.40$ 1.13$ 2.88$ 2.24 Discontinued operations (0.01)(0.01)(0.01)(0.02) Net income $ 1.39$ 1.12$ 2.87$ 2.22 Amounts attributable to Encompass Health common shareholders:Income from continuing operations $ 143.0$ 115.3$ 295.0$ 229.1 Loss from discontinued operations, net of tax (0.9)(1.2)(1.4)(2.5) Net income attributable to Encompass Health $ 142.1$ 114.1$ 293.6$ 226.6 Encompass Health Corporation and SubsidiariesCondensed Consolidated Balance Sheets(Unaudited) June 30, 2025December 31, 2024(In Millions) AssetsCurrent assets:Cash and cash equivalents $ 99.1$ 85.4 Restricted cash 38.337.7 Accounts receivable 612.5598.8 Other current assets 168.2165.0 Total current assets 918.1886.9 Property and equipment, net 3,820.33,643.1 Operating lease right-of-use assets 215.5203.7 Goodwill 1,303.01,284.0 Intangible assets, net 295.9297.8 Other long-term assets 232.9219.2 Total assets $ 6,785.7$ 6,534.7 Liabilities and Shareholders' EquityCurrent liabilities:Current portion of long-term debt $ 139.2$ 138.6 Current operating lease liabilities 25.526.3 Accounts payable 174.5171.0 Accrued expenses and other current liabilities 525.9505.1 Total current liabilities 865.1841.0 Long-term debt, net of current portion 2,320.32,359.2 Long-term operating lease liabilities 200.7189.7 Deferred income tax liabilities 110.6105.2 Other long-term liabilities 200.8190.4 Total liabilities 3,697.53,685.5 Commitments and contingenciesRedeemable noncontrolling interests 55.156.5 Shareholders' equity:Encompass Health shareholders' equity 2,280.12,067.0 Noncontrolling interests 753.0725.7 Total shareholders' equity 3,033.12,792.7 Total liabilities and shareholders' equity $ 6,785.7$ 6,534.7 Encompass Health Corporation and SubsidiariesCondensed Consolidated Statements of Cash Flows (Unaudited) Six Months Ended June 30,20252024(In Millions) Cash flows from operating activities:Net income $ 381.4$ 285.3 Loss from discontinued operations, net of tax 1.42.5 Adjustments to reconcile net income to net cash provided by operating activities—Depreciation and amortization 159.1143.2 Stock-based compensation 23.822.9 Deferred tax expense 5.34.2 Other, net 1.114.2 Change in assets and liabilities, net of acquisitions—Accounts receivable (15.7)0.9 Other assets (16.5)(48.4) Accounts payable (2.5)1.8 Other liabilities 23.332.3 Net cash used in operating activities of discontinued operations (1.9)(2.7) Total adjustments 176.0168.4 Net cash provided by operating activities 558.8456.2 Cash flows from investing activities:Purchases of property, equipment, and intangible assets (320.0)(296.3) Proceeds from sale of restricted investments 132.017.0 Purchases of restricted investments (127.8)(8.2) Other, net (8.1)(0.6) Net cash used in investing activities (323.9)(288.1) Cash flows from financing activities:Principal payments on debt, including pre-payments (10.7)(2.4) Borrowings on revolving credit facility 60.050.0 Payments on revolving credit facility (80.0)(50.0) Principal payments under finance lease obligations (11.6)(10.7) Repurchases of common stock, including fees and expenses (56.8)(16.8) Dividends paid on common stock (35.1)(30.8) Distributions paid to noncontrolling interests of consolidated affiliates (73.3)(52.5) Taxes paid on behalf of employees for shares withheld (19.9)(12.1) Contributions from noncontrolling interests of consolidated affiliates —33.3 Other, net 6.81.8 Net cash used in financing activities (220.6)(90.2) Increase in cash, cash equivalents, and restricted cash 14.377.9 Cash, cash equivalents, and restricted cash at beginning of period 123.1104.2 Cash, cash equivalents, and restricted cash at end of period $ 137.4$ 182.1 Encompass Health Corporation and SubsidiariesSupplemental InformationEarnings Per Share Three MonthsEnded June 30,Six MonthsEnded June 30,2025202420252024(In Millions, Except Per Share Data) Adjusted EBITDA $ 318.6$ 271.8$ 632.2$ 544.8 Depreciation and amortization (79.9)(72.9)(159.1)(143.2) Interest expense and amortization of debt discounts and fees (30.4)(34.3)(62.2)(69.5) Stock-based compensation (14.3)(13.6)(23.8)(22.9) (Loss) gain on disposal or impairment of assets (0.3)3.0(0.5)(10.7)193.7154.0386.6298.5 Items not indicative of ongoing operating performance:Change in fair market value of equity securities 0.3(0.4)1.0(0.1) Asset impairment impact on noncontrolling interests ———7.3 Pre-tax income 194.0153.6387.6305.7 Income tax expense (51.0)(38.3)(92.6)(76.6) Income from continuing operations (1) $ 143.0$ 115.3$ 295.0$ 229.1 Basic shares 100.699.9100.699.9 Diluted shares 102.3102.0102.2102.1 Basic earnings per share (1) $ 1.42$ 1.14$ 2.92$ 2.28 Diluted earnings per share (1) $ 1.40$ 1.13$ 2.88$ 2.24 (1) Income from continuing operations attributable to Encompass Health Encompass Health Corporation and SubsidiariesSupplemental InformationAdjusted Earnings Per Share Q26 Months2025202420252024 Earnings per share, as reported $ 1.40$ 1.13$ 2.88$ 2.24 Adjustments, net of tax:Asset impairment impact ———0.02 Income tax adjustments —(0.02)(0.11)(0.03) Change in fair market value of equity securities ——(0.01)— Adjusted earnings per share* $ 1.40$ 1.11$ 2.77$ 2.23* Adjusted EPS may not sum due to rounding. Encompass Health Corporation and SubsidiariesSupplemental InformationReconciliation of Net Cash Provided by Operating Activities to Adjusted EBITDA Three Months EndedJune 30,Six Months EndedJune 30,2025202420252024(In Millions) Net cash provided by operating activities $ 270.2$ 217.4$ 558.8$ 456.2 Interest expense and amortization of debt discounts and fees 30.434.362.269.5 Gain (loss) on sale of investments, excluding impairments 3.3(0.1)3.21.2 Equity in net income of nonconsolidated affiliates 1.41.42.32.1 Net income attributable to noncontrolling interests in continuing operations (42.8)(32.4)(87.8)(58.7) Amortization of debt-related items (2.4)(2.5)(4.8)(4.9) Distributions from nonconsolidated affiliates (0.9)(1.2)(1.4)(2.0) Current portion of income tax expense 54.540.687.372.4 Change in assets and liabilities 3.911.811.413.4 Cash used in operating activities of discontinued operations 1.22.01.92.7 Asset impairment impact on noncontrolling interests ———(7.3) Change in fair market value of equity securities (0.3)0.4(1.0)0.1 Other 0.10.10.10.1 Adjusted EBITDA $ 318.6$ 271.8$ 632.2$ 544.8 Encompass Health Corporation and SubsidiariesSupplemental InformationReconciliation of Income from Continuing Operations Attributable to Encompass Health per Diluted Share to Adjusted Earnings Per Share For the Three Months Ended June 30, 2025AdjustmentsAs ReportedIncome Tax AdjustmentsChange in Fair Market Valueof Equity SecuritiesAs Adjusted(In Millions, Except Per Share Amounts) Adjusted EBITDA* $ 318.6$ —$ —$ 318.6 Depreciation and amortization (79.9)——(79.9) Interest expense and amortization of debt discounts and fees (30.4)——(30.4) Stock-based compensation (14.3)——(14.3) Loss on disposal or impairment of assets (0.3)——(0.3) Change in fair market value of equity securities 0.3—(0.3)— Income from continuing operations before income tax expense 194.0—(0.3)193.7 Provision for income tax expense (51.0)0.40.1(50.5) Income from continuing operations attributable to Encompass Health $ 143.0$ 0.4$ (0.2)$ 143.2 Diluted earnings per share from continuing operations** $ 1.40$ —$ —$ 1.40 Diluted shares used in calculation 102.3* See reconciliation of net income to Adjusted EBITDA. ** Adjusted EPS may not sum across due to rounding. Encompass Health Corporation and SubsidiariesSupplemental InformationReconciliation of Income from Continuing Operations Attributable to Encompass Health per Diluted Share to Adjusted Earnings Per ShareFor the Three Months Ended June 30, 2024AdjustmentsAs ReportedIncome TaxAdjustmentsChange in FairMarket Valueof Equity SecuritiesAsAdjusted(In Millions, Except Per Share Amounts) Adjusted EBITDA* $ 271.8$ —$ —$ 271.8 Depreciation and amortization (72.9)——(72.9) Interest expense and amortization of debt discounts and fees (34.3)——(34.3) Stock-based compensation (13.6)——(13.6) Gain on disposal or impairment of assets 3.0——3.0 Change in fair market value of equity securities (0.4)—0.4— Income from continuing operations before income tax expense 153.6—0.4154.0 Provision for income tax expense (38.3)(2.4)(0.1)(40.8) Income from continuing operations attributable to Encompass Health $ 115.3$ (2.4)$ 0.3$ 113.2 Diluted earnings per share from continuing operations** $ 1.13$ (0.02)$ —$ 1.11 Diluted shares used in calculation 102.0* See reconciliation of net income to Adjusted EBITDA. ** Adjusted EPS may not sum across due to rounding. Encompass Health Corporation and SubsidiariesSupplemental InformationReconciliation of Income from Continuing Operations Attributable to Encompass Health per Diluted Share to Adjusted Earnings Per Share For the Six Months Ended June 30, 2025AdjustmentsAs ReportedIncome TaxAdjustmentsChange in FairMarket Valueof Equity SecuritiesAsAdjusted(In Millions, Except Per Share Amounts) Adjusted EBITDA* $ 632.2$ —$ —$ 632.2 Depreciation and amortization (159.1)——(159.1) Interest expense and amortization of debt discounts and fees (62.2)——(62.2) Stock-based compensation (23.8)——(23.8) Loss on disposal or impairment of assets (0.5)——(0.5) Change in fair market value of equity securities 1.0—(1.0)— Income from continuing operations before income tax expense 387.6—(1.0)386.6 Provision for income tax expense (92.6)(11.6)0.3(103.9) Income from continuing operations attributable to Encompass Health $ 295.0$ (11.6)$ (0.7)$ 282.7 Diluted earnings per share from continuing operations** $ 2.88$ (0.11)$ (0.01)$ 2.77 Diluted shares used in calculation 102.2* See reconciliation of net income to Adjusted EBITDA. ** Adjusted EPS may not sum across due to rounding. Encompass Health Corporation and SubsidiariesSupplemental InformationReconciliation of Income from Continuing Operations Attributable to Encompass Health per Diluted Share to Adjusted Earnings Per Share For the Six Months Ended June 30, 2024AdjustmentsAs Reported AssetImpairmentImpactIncome Tax AdjustmentsChange in FairMarket Valueof EquitySecuritiesAs Adjusted(In Millions, Except Per Share Amounts) Adjusted EBITDA* $ 544.8 $ —$ —$ —$ 544.8 Depreciation and amortization (143.2) ———(143.2) Interest expense and amortization of debt discounts and fees (69.5) ———(69.5) Stock-based compensation (22.9) ———(22.9) Loss on disposal or impairment of assets (10.7) 10.4——(0.3) Change in fair market value of equity securities (0.1) ——0.1— Asset impairment impact on noncontrolling interests 7.3 (7.3)——— Income from continuing operations before income tax expense 305.7 3.1—0.1308.9 Provision for income tax expense (76.6) (1.3)(3.0)—(80.9) Income from continuing operations attributable to Encompass Health $ 229.1 $ 1.8$ (3.0)$ 0.1$ 228.0 Diluted earnings per share from continuing operations** $ 2.24 $ 0.02$ (0.03)$ —$ 2.23 Diluted shares used in calculation 102.1 * See reconciliation of net income to Adjusted EBITDA. ** Adjusted EPS may not sum across due to rounding. Encompass Health Corporation and SubsidiariesSupplemental InformationReconciliation of Net Income to Adjusted EBITDA Three Months EndedJune 30,Six Months EndedJune 30,2025202420252024(In Millions) Net income $ 184.9$ 146.5$ 381.4$ 285.3 Loss from discontinued operations, net of tax, attributable to Encompass Health 0.91.21.42.5 Net income attributable to noncontrolling interests included in continuing operations (42.8)(32.4)(87.8)(58.7) Provision for income tax expense 51.038.392.676.6 Interest expense and amortization of debt discounts and fees 30.434.362.269.5 Depreciation and amortization 79.972.9159.1143.2 Loss (gain) on disposal or impairment of assets 0.3(3.0)0.510.7 Stock-based compensation 14.313.623.822.9 Change in fair market value of equity securities (0.3)0.4(1.0)0.1 Asset impairment impact on noncontrolling interests ———(7.3) Adjusted EBITDA $ 318.6$ 271.8$ 632.2$ 544.8 Encompass Health Corporation and SubsidiariesSupplemental InformationReconciliation of Net Cash Provided by Operating Activities to Adjusted Free Cash Flow Three Months EndedJune 30,Six Months Ended June 30,2025202420252024(In Millions) Net cash provided by operating activities $ 270.2$ 217.4$ 558.8$ 456.2 Impact of discontinued operations 1.22.01.92.7 Net cash provided by operating activities of continuing operations 271.4219.4560.7458.9 Capital expenditures for maintenance (45.1)(48.9)(79.1)(87.6) Distributions paid to noncontrolling interests of consolidated affiliates (40.4)(27.8)(73.3)(52.5) Items not indicative of ongoing operating performance:Transaction costs and related liabilities —(0.2)—(8.7) Adjusted free cash flow $ 185.9$ 142.5$ 408.3$ 310.1 For the three months ended June 30, 2025, net cash used in investing activities was $165.4 million and resulted primarily from capital expenditures. Net cash used in financing activities during the three months ended June 30, 2025 was $90.2 million and resulted primarily from distributions paid to noncontrolling interests of consolidated affiliates, repurchases of common stock, net debt payments, and cash dividends paid on common stock. For the three months ended June 30, 2024, net cash used in investing activities was $158.4 million and resulted primarily from capital expenditures. Net cash used in financing activities during the three months ended June 30, 2024 was $49.6 million and resulted primarily from distributions paid to noncontrolling interests of consolidated affiliates, cash dividends paid on common stock, and repurchases of common stock partially offset by contributions from noncontrolling interests of consolidated affiliates. For the six months ended June 30, 2025, net cash used in investing activities was $323.9 million and resulted primarily from capital expenditures. Net cash used in financing activities during the six months ended June 30, 2025 was $220.6 million and resulted primarily from distributions paid to noncontrolling interests of consolidated affiliates, repurchases of common stock, net debt payments, and cash dividends paid on common stock. For the six months ended June 30, 2024, net cash used in investing activities was $288.1 million and resulted primarily from capital expenditures. Net cash used in financing activities during the six months ended June 30, 2024 was $90.2 million and resulted primarily from distributions paid to noncontrolling interests of consolidated affiliates, cash dividends paid on common stock, and repurchases of common stock partially offset by contributions from noncontrolling interests of consolidated affiliates. Encompass Health Corporation and SubsidiariesForward-Looking Statements Statements contained in this press release and the supplemental information which are not historical facts, such as those relating to the business, strategy, outlook, growth targets and guidance considerations, dividend strategies, effective income tax rates, cost trends, legislative and regulatory developments or their impacts, financial guidance, ability to return value to shareholders, projected capital expenditures, acquisition opportunities, development projects, addressable market size, other balance sheet and cash flow plans, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In addition, Encompass Health, through its senior management, may from time to time make forward-looking public statements concerning the matters described herein. All such estimates, projections, and forward-looking information speak only as of the date hereof, and Encompass Health undertakes no duty to publicly update or revise such forward-looking information, whether as a result of new information, future events, or otherwise. Such forward-looking statements are necessarily estimates based upon current information and involve a number of risks and uncertainties. Actual events or results may differ materially from those anticipated in these forward-looking statements as a result of a variety of factors. While it is impossible to identify all such factors, factors which could cause actual events or results to differ materially from those estimated by Encompass Health include, but are not limited to, infectious disease outbreak, including the speed, depth, geographic reach and duration of its spread, which could decrease our patient volumes and revenues and lead to staffing and supply shortages and associated cost increases; Encompass Health's infectious disease prevention and control efforts; the demand for Encompass Health's services, including based on any downturns in the economy, consumer confidence, or the capital markets; the price of Encompass Health's common stock as it affects Encompass Health's willingness and ability to repurchase shares and the financial and accounting effects of any repurchases; any adverse outcome of various lawsuits, claims, and legal or regulatory proceedings involving Encompass Health, including any matters related to yet undiscovered issues, if any, in acquired operations; Encompass Health's ability to attract and retain key management personnel; potential disruptions, breaches, or other incidents affecting the proper operation, availability, or security of Encompass Health's or its vendors' or partners' information systems, including unauthorized access to or theft of patient, business associate, or other sensitive information or inability to provide patient care because of system unavailability; Encompass Health's ability to successfully complete and integrate de novo developments, acquisitions, investments, and joint ventures consistent with its growth strategy; Encompass Health's ability to realize construction time and cost savings from prefabrication of hospitals; increases in Medicare audit activity, including increased use of sampling and extrapolation, resulting in additional unpaid reimbursement claims and an increase in the backlog of appealed claims denials; changes, delays in (including in connection with resolution of Medicare payment reviews or appeals), or suspension of reimbursement for Encompass Health's services by governmental or private payors; changes in the regulation of the healthcare industry at either or both of the federal and state levels, including as part of national healthcare reform and deficit reduction and Encompass Health's ability to adapt operations to those changes, including in connection with the CMS inpatient rehabilitation review choice demonstration project; competitive pressures in the healthcare industry and Encompass Health's response thereto; Encompass Health's ability to obtain and retain favorable arrangements with third-party payors; Encompass Health's ability to control costs, particularly labor and employee benefit costs, including group medical expenses; adverse effects resulting from coverage determinations made by Medicare Administrative Contractors regarding its Medicare reimbursement claims and lengthening delays in Encompass Health's ability to recover improperly denied claims through the administrative appeals process on a timely basis; Encompass Health's ability to adapt to changes in the healthcare delivery system, including value-based purchasing and involvement in coordinated care initiatives or programs that may arise with its referral sources; Encompass Health's ability to attract and retain nurses, therapists, and other healthcare professionals in a highly competitive environment with often severe staffing shortages, which may be worsened by infectious disease outbreaks, and the impact on Encompass Health's labor expenses from potential union activity, staffing shortages, and competitive compensation practices; general conditions in the economy and capital markets, including any instability or uncertainty related to trade war, armed conflict or an act of terrorism, governmental impasse over approval of the United States federal budget, an increase in the debt ceiling, or an international sovereign debt crisis; the increase in the cost of, or the decrease in the availability of, construction materials and necessary supplies, including as a result of tariffs and import restrictions; the increase in the costs of defending and insuring against alleged professional liability claims, and Encompass Health's ability to predict the estimated costs related to such claims; and other factors which may be identified from time to time in Encompass Health's SEC filings and other public announcements, including Encompass Health's Form 10‑K for the year ended December 31, 2024 and Form 10-Q for the quarters ended March 31, 2025 and June 30, 2025, when filed. Media ContactPolly Manuel, 205 Investor Relations ContactMark Miller, 205 View original content to download multimedia: SOURCE Encompass Health Corp.
